|Mr. R. Lee Buckler L.L.B., B.Ed., LLB||Pres, CEO, Corp. Sec. & Director||240k||N/A||1966|
|Mr. Simon S. Ma CPA, B.A., CA||CFO & Director of Fin.||96k||N/A||1965|
|Dr. Kevin John McElwee||Chief Scientific Officer||35k||N/A||1970|
|Dr. Rolf Hoffmann||Chief Medical Officer||44.88k||N/A||1962|
|Mr. Darrell Panich M.Sc, PMP, CPM||Clinical Consultant||N/A||N/A||1972|
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that has completed Phase I clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase II clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
RepliCel Life Sciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.